Ontology highlight
ABSTRACT:
INSTRUMENT(S): LTQ Orbitrap Elite
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Cell Culture
SUBMITTER: Debora Bonenfant
LAB HEAD: Debora Bonenfant, Novartis Institutes for BioMedical Research
PROVIDER: PXD008546 | Pride | 2018-01-31
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
EL150388_Nilotinib_Invivo1a.raw | Raw | |||
EL150389_Nilotinib_Invivo1b.raw | Raw | |||
EL150391_DMSO_Invivo1a.raw | Raw | |||
EL150392_DMSO_Invivo1b.raw | Raw | |||
EL15552_DMSO_Invivo2a.raw | Raw |
Items per page: 1 - 5 of 12 |
EMBO molecular medicine 20180401 4
The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion <i>in vitro</i> and reduces their metastatic potential in intrasplenic tumour mouse models. Nilotinib acts by inhibiting the kinase activity of DDR1, a receptor tyrosine kinase for collagens, which we identified as a RAS-independent inducer of CRC metastasis. Using quantitative phos ...[more]